纵观视网膜母细胞瘤的经静脉全身化学治疗与经眼动脉灌注化学治疗  

The key points in intravenous chemotherapy and intra-arterial chemotherapy on retinoblastoma treatment

作　　者：赵军阳[1] 张诚玥[1] 

机构地区：[1]首都医科大学附属北京儿童医院眼科儿科学国家重点学科国家儿童医学中心,100045

出　　处：《中华眼科杂志》2017年第8期566-569,共4页Chinese Journal of Ophthalmology

摘　　要：经静脉全身化学治疗和经眼动脉灌注化学治疗（IAC）均是临床视网膜母细胞瘤（RB）的一线治疗方法。但是，随着IAC方法在眼球保存率方面的优势不断突显，其是否可以取代经静脉全身化学治疗方法存在诸多争议。本文通过回顾两种治疗方法各自的优缺点，提出应针对不同RB患儿采用个性化综合治疗方案，以期达到最佳的治疗效果。Intravenous chemotherapy and intra-arterial chemotherapy （IAC） both are the first-line treatment for retinoblastoma （RB） in clinical. There is a controversy on if intra-arterial chemotherapy can substitute the intravenous chemotherapy due to its high eye salvage rate in retinoblastoma therapy. The advantages and disadvantages of these two therapies were retrospectively reviewed here to suggest an individualized and comprehensive regimen for getting the proximal results for retinoblastoma afflicted children.

关 键 词：视网膜母细胞瘤 投药 静脉内 输注 动脉内 眼动脉 肿瘤治疗方案 

分 类 号：R739.7[医药卫生—肿瘤]